DNDi aims to:

  • Deliver new oral treatments to cure sleeping sickness that are safe, affordable, effective and easy to use, and support the sustainable elimination of the disease.

 

The current sleeping sickness portfolio includes:

 Research

Discovery

SCYX-1330682 & SCYX-1608210 Oxaboroles

Development

Development

Acoziborole (SCYX-7158)
Fexinidazole for T.b. rhodesiense

 Implementation

Implementation

Fexinidazole for T.b. gambiense
Nitfurtimox-eflornithine combination therapy (NECT)

 

For more details on each project, see DNDi‘s Global Portfolio